$ARMP
Armata Pharmaceuticals, Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024012061 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.439M
YoY Change 46.34%
% of Gross Profit
Research & Development $9.485M $8.475M
YoY Change 18.89% 2.62%
% of Gross Profit
Depreciation & Amortization $300.0K $300.0K
YoY Change 50.0% 50.0%
% of Gross Profit
Operating Expenses $12.73M $11.91M
YoY Change 10.1% 12.3%
Operating Profit -$9.756M -$11.91M
YoY Change -5.61% 23.73%
Interest Expense $2.718M
YoY Change -55.31%
% of Operating Profit
Other Income/Expense, Net $4.275M $20.90M
YoY Change -120.53% 243.64%
Pretax Income $8.986M
YoY Change -353.34%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$5.481M $8.986M
YoY Change -82.41% -353.34%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15 $0.25
Diluted Earnings Per Share -$0.15 -$0.25
COMMON SHARES
Basic Shares Outstanding 36.18M 36.15M
Diluted Shares Outstanding 36.18M 58.25M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.41M
YoY Change 111.99%
Cash & Equivalents $17.10M $26.40M
Short-Term Investments
Other Short-Term Assets $2.219M $1.242M
YoY Change -73.88% -85.61%
Inventory
Prepaid Expenses
Receivables
Other Receivables $2.219M $1.242M
Total Short-Term Assets $22.39M $30.90M
YoY Change -38.8% 15.16%
LONG-TERM ASSETS
Property, Plant & Equipment $13.62M $13.47M
YoY Change 47.2% 52.99%
Goodwill $3.490M $3.490M
YoY Change 0.0% 0.0%
Intangibles $10.26M $10.26M
YoY Change 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $755.0K $1.039M
YoY Change -69.43% -57.64%
Total Long-Term Assets $75.85M $77.41M
YoY Change -0.43% 4.08%
TOTAL ASSETS
Total Short-Term Assets $22.39M $30.90M
Total Long-Term Assets $75.85M $77.41M
Total Assets $98.24M $108.3M
YoY Change -12.88% 7.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.815M $1.743M
YoY Change -51.88% -81.81%
Accrued Expenses $8.246M
YoY Change -47.23%
Deferred Revenue
YoY Change
Short-Term Debt $48.26M
YoY Change 83.14%
Long-Term Debt Due $63.13M
YoY Change
Total Short-Term Liabilities $118.2M $123.2M
YoY Change 440.14% 138.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $28.16M
YoY Change 2.65%
Total Long-Term Liabilities $28.16M
YoY Change 2.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $118.2M $123.2M
Total Long-Term Liabilities $28.16M
Total Liabilities $149.2M $154.4M
YoY Change 19.23% 88.15%
SHAREHOLDERS EQUITY
Retained Earnings -$330.3M -$324.9M
YoY Change 14.29% 26.02%
Common Stock $362.0K $362.0K
YoY Change 0.28% 0.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$50.97M -$46.10M
YoY Change
Total Liabilities & Shareholders Equity $98.24M $108.3M
YoY Change -12.88% 7.02%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$5.481M $8.986M
YoY Change -82.41% -353.34%
Depreciation, Depletion And Amortization $300.0K $300.0K
YoY Change 50.0% 50.0%
Cash From Operating Activities -$10.18M
YoY Change -15.61%
INVESTING ACTIVITIES
Capital Expenditures $1.366M
YoY Change 515.32%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.366M
YoY Change 515.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 88.00K
YoY Change -123.91%
NET CHANGE
Cash From Operating Activities -10.18M
Cash From Investing Activities -1.366M
Cash From Financing Activities 88.00K
Net Change In Cash -11.46M
YoY Change -9.45%
FREE CASH FLOW
Cash From Operating Activities -$10.18M
Capital Expenditures $1.366M
Free Cash Flow -$11.54M
YoY Change -6.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0000921114
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36122932
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36155992
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37544
dei Entity Registrant Name
EntityRegistrantName
ARMATA PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1549568
dei Entity Address Address Line1
EntityAddressAddressLine1
5005 McConnell Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90066
dei City Area Code
CityAreaCode
310
dei Local Phone Number
LocalPhoneNumber
665-2928
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ARMP
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36183067
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26405000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13523000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3256000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2265000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1242000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3363000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
30903000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19151000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5480000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5720000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13474000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12559000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43671000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44717000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10256000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10256000
CY2024Q2 us-gaap Goodwill
Goodwill
3490000
CY2023Q4 us-gaap Goodwill
Goodwill
3490000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1039000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2470000
CY2024Q2 us-gaap Assets
Assets
108313000
CY2023Q4 us-gaap Assets
Assets
98363000
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3851000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5689000
CY2024Q2 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1222000
CY2023Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
768000
CY2024Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
48261000
CY2024Q2 armp Long Term Debt Current Maturities Other Than Convertible Debt Current
LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent
63127000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6596000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9481000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
124000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
523000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
123181000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16461000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28156000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28583000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
58633000
CY2023Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
23674000
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3077000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3077000
CY2024Q2 us-gaap Liabilities
Liabilities
154414000
CY2023Q4 us-gaap Liabilities
Liabilities
130428000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36155992
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36122932
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36122932
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
362000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
361000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
278391000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
276393000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-324854000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308819000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-46101000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-32065000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108313000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98363000
CY2023Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
980000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
966000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1776000
CY2024Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8475000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8259000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
16491000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
17863000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3439000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2350000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6617000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4888000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
11914000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
10609000
us-gaap Operating Expenses
OperatingExpenses
23108000
us-gaap Operating Expenses
OperatingExpenses
22751000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11914000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9629000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22142000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20975000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
221000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
46000
us-gaap Investment Income Interest
InvestmentIncomeInterest
273000
us-gaap Investment Income Interest
InvestmentIncomeInterest
64000
CY2024Q2 us-gaap Interest Expense
InterestExpense
2718000
us-gaap Interest Expense
InterestExpense
4538000
CY2024Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
23397000
CY2023Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
6036000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
10372000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
2874000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20900000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6082000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6107000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2938000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
8986000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3547000
us-gaap Net Income Loss
NetIncomeLoss
-16035000
us-gaap Net Income Loss
NetIncomeLoss
-18037000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36154521
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36068130
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36139873
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36056649
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58246626
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56544698
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58231978
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36056649
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
22447000
CY2023Q2 armp Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings
RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
18000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
261000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3547000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
19143000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-56510000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
88000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1335000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
8986000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-46101000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
36080000
armp Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings
RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
18000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1118000
us-gaap Net Income Loss
NetIncomeLoss
-18037000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
19143000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-32065000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
130000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1869000
us-gaap Net Income Loss
NetIncomeLoss
-16035000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-46101000
us-gaap Profit Loss
ProfitLoss
-16035000
us-gaap Profit Loss
ProfitLoss
-18037000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
632000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
458000
us-gaap Share Based Compensation
ShareBasedCompensation
1869000
us-gaap Share Based Compensation
ShareBasedCompensation
1118000
armp Increase Decrease Fair Value Of Liabilities
IncreaseDecreaseFairValueOfLiabilities
-10372000
armp Increase Decrease Fair Value Of Liabilities
IncreaseDecreaseFairValueOfLiabilities
-2874000
us-gaap Other Noncash Expense
OtherNoncashExpense
4538000
armp Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-960000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2561000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2207000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2142000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
116000
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
454000
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-730000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3226000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-7474000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20761000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29630000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1616000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2232000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1616000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2232000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
29226000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
34889000
armp Proceeds From Exercise Of Warrants And Stock Options
ProceedsFromExerciseOfWarrantsAndStockOptions
130000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35019000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29226000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12642000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2636000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19243000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20812000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31885000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18176000
us-gaap Contribution Of Property
ContributionOfProperty
148000
us-gaap Contribution Of Property
ContributionOfProperty
3416000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26405000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12456000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5480000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5720000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31885000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18176000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-324900000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to convertible debt, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risks and Certain Other Risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and restricted cash. As of June 30, 2024, cash equivalents and restricted cash was invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions in accordance with the Company’s investment policy, to a concentration limit per issuer or sector. These are investment assets and are classified as cash equivalents in the condensed consolidated balance sheets as their original maturities are less than three months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other receivables represent amounts due from the Medical Technology Enterprise Consortium (“MTEC”) (Note 13) and reimbursement for tenant improvements (Note 12).</p>
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
21102000
CY2024Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
48261000
CY2023Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
58633000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
8986000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3547000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16035000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18037000
CY2024Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-23397000
CY2023Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-6036000
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-10372000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14411000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9583000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-26407000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-18037000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36154521
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36068130
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36139873
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36056649
CY2024Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
22092105
CY2023Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
20476568
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
22092105
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58246626
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56544698
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58231978
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36056649
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24301584
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
44024924
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25927000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24380000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12453000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11821000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13474000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12559000
CY2024Q2 us-gaap Depreciation
Depreciation
300000
CY2023Q2 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
600000
us-gaap Depreciation
Depreciation
500000
CY2024Q2 armp Construction In Progress And Fixed Assets Not In Use Included In Laboratory And Manufacturing Equipment
ConstructionInProgressAndFixedAssetsNotInUseIncludedInLaboratoryAndManufacturingEquipment
9600000
CY2023Q4 armp Construction In Progress And Fixed Assets Not In Use Included In Laboratory And Manufacturing Equipment
ConstructionInProgressAndFixedAssetsNotInUseIncludedInLaboratoryAndManufacturingEquipment
8100000
CY2024Q2 armp Tenant Improvement Receivable Current
TenantImprovementReceivableCurrent
748000
CY2023Q4 armp Tenant Improvement Receivable Current
TenantImprovementReceivableCurrent
1835000
CY2024Q2 armp Grant And Award Receivable Current
GrantAndAwardReceivableCurrent
494000
CY2023Q4 armp Grant And Award Receivable Current
GrantAndAwardReceivableCurrent
1528000
CY2024Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1242000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3363000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1743000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1585000
CY2024Q2 armp Accrued Liabilities Clinical Trial
AccruedLiabilitiesClinicalTrial
1680000
CY2023Q4 armp Accrued Liabilities Clinical Trial
AccruedLiabilitiesClinicalTrial
3021000
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
428000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
1083000
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3851000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5689000
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19365847
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4645737
CY2024Q2 us-gaap Employee Stock Ownership Plan Esop Number Of Committed To Be Released Shares
EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
11890
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19365847
CY2024Q2 armp Shares Issuable Upon Conversion Of Convertible Debt
SharesIssuableUponConversionOfConvertibleDebt
22092105
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
48885738
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2480159
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3165216
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.04
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
429000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1784054
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.38
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
37282
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
24000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
266251
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.36
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4645737
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.83
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
144000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4645737
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.83
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
144000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2627743
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M18D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
144000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1335000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
261000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1869000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1118000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 armp Annual Increase In Rent Percentage
AnnualIncreaseInRentPercentage
0.03
CY2021Q4 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P16Y
CY2021Q4 armp Base Annual Rent To Be Paid Year Three
BaseAnnualRentToBePaidYearThree
300000
CY2021Q4 armp Maximum Allowance For Tenant Improvements Receivable
MaximumAllowanceForTenantImprovementsReceivable
7300000
CY2024Q2 armp Proceeds From Tenant Allowances
ProceedsFromTenantAllowances
6500000
CY2021Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
5000000.0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4356000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5307000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5466000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5452000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5616000
CY2024Q2 armp Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
43439000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
69636000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
34884000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
34752000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6596000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28156000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
2000000.0
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000
us-gaap Operating Lease Expense
OperatingLeaseExpense
4200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3600000
CY2024Q2 us-gaap Variable Lease Payment
VariableLeasePayment
400000
CY2023Q2 us-gaap Variable Lease Payment
VariableLeasePayment
200000
us-gaap Variable Lease Payment
VariableLeasePayment
1000000.0
us-gaap Variable Lease Payment
VariableLeasePayment
500000
us-gaap Operating Lease Payments
OperatingLeasePayments
5149000
us-gaap Operating Lease Payments
OperatingLeasePayments
10608000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y3M
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y9M14D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.139
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.139
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-012061-index-headers.html Edgar Link pending
0001558370-24-012061-index.html Edgar Link pending
0001558370-24-012061.txt Edgar Link pending
0001558370-24-012061-xbrl.zip Edgar Link pending
armp-20240630.xsd Edgar Link pending
armp-20240630x10q.htm Edgar Link pending
armp-20240630x10q001.jpg Edgar Link pending
armp-20240630xex31d1.htm Edgar Link pending
armp-20240630xex31d2.htm Edgar Link pending
armp-20240630xex32d1.htm Edgar Link pending
armp-20240630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
armp-20240630_def.xml Edgar Link unprocessable
armp-20240630_lab.xml Edgar Link unprocessable
armp-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
armp-20240630x10q_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
armp-20240630_cal.xml Edgar Link unprocessable